**Name of journal: *World Journal of Clinical Urology***

**ESPS Manuscript NO: 10984**

**Columns: REVIEW**

**Perspective of novel therapeutic medicines targeting androgen signaling pathway in castration resistance prostate cancer**

Obinata D *et al.* Novel therapeutics for castration resistance prostate cancer

Daisuke Obinata, Kyoko Fujiwara, Kenya Yamaguchi, Ken-ichi Takayama, Tomohiko Urano, Hiroki Nagase, Satoshi Inoue, Satoru Takahashi, Noboru Fukuda

**Daisuke Obinata, Kenya Yamaguchi, Satoru Takahashi,** Department of Urology, Nihon University School of Medicine, Tokyo 173-8610, Japan

**Kyoko Fujiwara,** Division of General Medicine, Department of Medicine, Nihon University School of Medicine, Tokyo 173-8610, Japan

**Ken-ichi Takayama, Tomohiko Urano, Satoshi Inoue,** Department of Anti-Aging Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan

**Hiroki Nagase,** Chiba Cancer Center Research Institute, Chiba 260-8717, Japan

**Noboru Fukuda,**Division of Life Science, Advanced Research Institute of Sciences and Humanities, Nihon University, Tokyo 173-8610, Japan

**Author contributions:** Obinata D, Fujiwara K, Yamaguchi K, Takayama K, Urano T, Nagase H, Inoue S, Takahashi S and Fukuda N solely contributed to this paper.

**Correspondence to: Noboru Fukuda, MD, PhD,** Division of Life Science, Advanced Research Institute of Sciences and Humanities, Nihon University, 30-1 Ooyaguchikamimachi, Itabashi, Tokyo 173-8610, Japan. fukuda.noboru@nihon-u.ac.jp

**Telephone:** +81-3-39728111 **Fax:** +81-3-39728666

**Received:** April 28, 2014 **Revised:** June 26, 2014

**Accepted:** July 27, 2014

**Published online:**

**Abstract**

Prostate cancer is the most common male malignant neoplasm. Androgens and the androgen receptor (AR) play a key role in the onset and progression of prostate cancer. The expression of the AR is still preserved in the majority of patients with castration-resistant prostate cancer (CRPC). CRPCs are considered to be induced by the following mechanisms: (1) sustained AR activation by enhancing intracellular conversion of adrenal androgens to dehydrotestosterone *via* a de novo route; (2) AR hypersensitivity; (3) promiscuous activation of AR signaling; and (4) outlaw pathways. Recent advances in the treatment of CRPC include novel medicines targeting AR signaling pathways. In addition, functional molecular studies have shown that some of the AR-regulated genes and AR co-regulators are prognostic markers and potential therapeutic targets for prostate cancer, particularly in the castration-resistant state. Therefore, identification of the AR signaling pathways responsible for establishment of CRPC is critical for developing new strategies for the treatment of CRPC.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Androgen receptor; Prostate cancer; Pyrrole-imidazole polyamide

**Core tip:** Prostate cancer is the most common male malignant neoplasm. Androgens and the androgen receptor (AR) play a key role in the onset and progression of prostate cancer. The expression of the AR is still preserved in the majority of patients with castration-resistant prostate cancer (CRPC). Therefore, identification of the AR signaling pathways responsible for establishment of CRPC is critical for developing new strategies for the treatment of CRPC.

Obinata D, Fujiwara K, Yamaguchi K, Takayama K, Urano T, Nagase H, Inoue S, Takahashi S, Fukuda N.Perspective of novel therapeutic medicines targeting androgen signaling pathway in castration resistance prostate cancer. *World J Clin Urol* 2014; In press

**INTRODUCTION**

Prostate cancer has been the most common male malignant neoplasm for more than 30 years and is the second leading cause of cancer-related death of men in the United States[1]. In Japan, partially because the diet seems to be being westernized, the incidence of prostate cancer has been increasing. The population of older males is becoming larger may also be a contributor.

Androgens and the androgen receptor (AR) play a key role in the onset and progression of prostate cancer. Functional AR are expressed during various stages of prostate carcinogenesis, from prostate intraepithelial neoplasia to locally advanced primary tumors. Approximately 80%–90% of prostate cancers are androgen-dependent at the time of diagnosis[2-4].

Since the discovery that the progression of prostate cancer could be inhibited by castration in the 1940s[5,6], hormonal therapy that specifically inhibits AR activity by using LHRH analog/antagonist, with/without anti-androgens (androgen deprivation therapy; ADT) has become the most effective and widely used palliative method for advanced and/or metastatic prostate cancer[7-9]. In the majority of patients, although ADT leads to a biochemical response for up to 3 years, the prostate cancer eventually continues to progress through cell transformation. Previously, these conditions were known by various names over the years, including hormone-resistant prostate cancer (HRPC) and androgen-insensitive prostate cancer. However, most recent reports indicate that AR is still expressed in the majority of ADT resistant cases, and expression of AR target genes, such as prostate-specific antigen (PSA), remains persistently high despite serum testosterone in the castrate range by surgical castration or ADT[9-11]. This condition is called castration-resistant prostate cancer (CRPC)[12]. The patients with CRPC demonstrates poor prognosis and associated with deterioration in quality of life, and few therapeutic options are currently available[13]. Therefore, it is important to understand the AR signaling pathway to develop an effective treatment for CRPC. In this review, we summarize the roles of the AR signaling pathway and novel therapeutic medicines that target this pathway in prostate cancer. We focus in particular on functional analyses of AR targets and indicate future directions of their therapeutic use.

**AR STRUCTURE**

The AR gene is a member of the steroid hormone receptor superfamily, which includes genes encoding receptors for estrogen, progesterone, glucocorticoids, mineralocorticoids, vitamin D, retinoic acid, and retinoid X receptor. Similar to many other steroid receptors, the AR is characterized by a modular structure consisting of distinct functional domains: a poorly conserved N-terminal domain (NTD; 555 amino acids coded by exon 1), a highly conserved DNA-binding domain (DBD; 68-amino acid coded by exon 2 and 3), a hinge region, and a moderately conserved ligand binding domain (LBD; 295 amino acids coded by exons 4–8)[14]. The AR NTD contains the major transactivation function of the AR, which is known as activation function (AF) 1, and consists of two transcriptional activation units (TAU): TAU-1 and TAU-5[15]. AF1 interacts with the LBD, the basal transcription factors TFIIF and TFIIH, members of the p160 family of nuclear receptor coactivator proteins and the general coactivator CREB-binding protein[16-28]. These reports also indicate that AF-1 is one of the major domains responsible for mediating AR transcriptional activity.

The DBD exerts important roles in mediating AR nuclear localization, homodimer formation, and specific DNA binding. Activated AR binds as a homodimer to specific DNA sequences called androgen response elements (AREs) located around the target genes[29]. These AREs can be classified into two types: canonical and non-canonical AREs[29]. Canonical AREs consist of inverted repeat of hexameric half-sites (5’-TGTTCT-3’) with a 3-bp spacer[30]. The non-canonical AREs have an atypical motif, and their binding specificity to steroid receptors is relatively weak, causing their requirement of coregulators[31,32]. Data indicate that some important androgen-regulated genes in prostate cancer are regulated by atypical AREs. The DBD contains two zinc finger domains. The first zinc finger contains a conserved P-box motif that binds the half site of the classical ARE. The second zinc finger contains a conserved D-box motif that functions to stabilize the DNA–receptor complex and to produce a receptor homodimer[33].

The LBD is located in the C-terminal region and comprises twelve -helices. The LBD assists in the binding of dihydrotestosterone (DHT), which is the first step of the androgen signaling pathway. Like the AF1 region in the NTD, the LBD contains an AF2 that interacts with co-regulators [the steroid receptor coactivator (SRC)/p160 family] to bind to the NTD[34,35]. Because AF2 shows a higher affinity for the NTD than the coactivator, interaction with the NTD is the primary role for AF2 rather than direct transcriptional activation. The LBD plays a key role in current ADT for prostate cancer. Although anti-androgens used in ADT, such as bicalutamide, block the activity of AF2 by binding to the LBD[36], point mutations in the AR in prostate cancer primarily occur in the regions of the LBD that include amino acids 670–676, 701–730, and 874–919, causing resistance to anti-androgens binding and cause proliferation in the presence of the anti-androgens[37-39].

**THE AR SIGNALING PATHWAY**

Androgens, the male sex steroids, regulate numerous physiological responses ranging from male sexual differentiation to the development of bone and muscle. The biological action of androgens is mediated through the AR. In prostate tissue, DHT is the primary ligand for the AR and is synthesized from testosterone by 5-reductase. The ligand-unbound AR is present primarily in the cytoplasm, where it interacts with heat shock proteins (Hsp)-90, -70, -56, cytoskeletal proteins, and other co-chaperones[40]. The AR-Hsp90 interaction is necessary to maintain the AR in a high-affinity ligand-binding conformation, suggesting that Hsp90 plays a key role in the activation of agonist-bound AR regulation of nuclear transfer, nuclear matrix binding, and transcriptional activity. Following DHT binding to the AR, the AR translocates into the nucleus, and binds to the ARE in the promoter and enhancer regions of target genes. For example, PSA is a typical product of AR-dependent gene and an important biomarker for prostate cancer.

The AR transcriptional complex is completed by recruitment of coregulators, which ultimately results in regulation of gene expression[36]. After the discovery of SRC-1, more than 200 nuclear receptor coregulators have been identified[41,42]. Coregulators were previously classified as either enhancing (coactivators) or repressing (corepressors) AR activity, and the requirements for coregulators vary among genes[43].

The AR is also regulated by post-translational modifications generated by signal transduction pathways. These modifications can be further divided into two categories: (1) reversible modifications of specific amino acid residues of target proteins (phosphorylation and acetylation); and (2) modifications involving addition of other proteins or polypeptides (ubiquitination and sumoylation). These changes have the potential to affect AR stability, subcellular localization, and interaction with other proteins, including coregulators.

**MECHANISMS OF CASTRATION RESISTANCE**

Castration resistance has been reported to be induced by: (1) sustained AR activation by enhancinged intracellular conversion of adrenal androgens to DHT via a de novo route[44]; (2) AR hypersensitivity[45]; (3) promiscuous activation of AR signaling; and (4) outlaw pathways[9]. AR hypersensitivity results in the facilitation of a susceptibility to androgen by variation of a coregulator or cytokine activity and overexpression of the androgen receptor. In addition, Cai *et al*[46] reported that prostate cancer cells incubated with levels of androgen comparable to those seen in castration decreased AR-induced LSD1 levels, which negatively regulates AR signaling, resulting in an increase in the expression of AR and of multiple genes that contribute to increased androgen synthesis and sensitivity in CRPC[46].

Promiscuous activation of the AR signaling pathway occurs in cases of AR structural change and when the AR combines with ligands other than androgen. This phenomenon induces the anti-androgen withdrawal syndrome, *i.e.,* anti-androgen itself serves as an accelerator of progression. Outlaw pathways include AR structural changes when androgen is absent or when cytokines other than androgen bind to the AR to activate a signaling pathway, resulting in a facilitation of an androgenic response in gene expression. The extragonadal androgen synthesized in adrenal or prostate cancer cells plays a key role in the occurrence of sustained AR activation. Androgen is a metabolite of cholesterol in the testis and adrenal gland. Most of its synthetases belong to the cytochrome P450 (CYP) family. CYP17 in particular has both 17-hydroxylase and 17, 20-lyase activity that plays an important role in the synthesis of adrenal androgen. Castration does not influence the synthesis of adrenal androgen. Adrenal androgen is converted into DHT by 5-reductase in prostate cancer cells. Affinity of DHT for the ligand-binding domain on the AR is higher than testosterone as a main ligand in prostate cells. Furthermore, the CRPC cells contain increased CYP17 activity with a new metabolic pathway that converts cholesterol to androgen. Thus, the expression of androgen-dependent genes is achieved by a very small amount of testosterone under castration[47].

**NEW THERAPEUTIC DRUGS TARGETING THE AR SIGNALING PATHWAY**

Standard therapeutic strategies for prostate cancers have recently been changed to utilize newly developed medicines for CRPCs. As described above, because androgen and the AR remaining in CRPC cells are important for cancer progression, novel medicines should be designed to target the androgen synthesis pathway or the AR signaling pathway (Figure 1). Here, we introduce these new medicines, including compounds currently being developed in Japan.

***Abiraterone***

Abiraterone is a dual inhibitor of the 17-hydroxylase and 17, 20-lyase expressed in testicular, adrenal, and prostatic tumor tissues. Ketoconazole, an azole antifungal medicine that has a similar target as abiraterone, initially showed a preferable outcome in patients with CRPC[48]. Ketoconazole inhibits both testicular and adrenal androgen biosynthesis by targeting cytochrome P450 isozyme 3A4 and 17, 20-lyase. However ketoconazole results in severe toxicities because it has low specificity for the CYP17 family. Based on these pieces of evidence, abiraterone was selected for development at the Institute of Cancer Research in the UK as a selective inhibitor of CYP17. The multicenter phase III randomized placebo-controlled trial COU-AA-301 evaluated the efficacy of abiraterone compared to docetaxel for men with progressive CRPC[49]. The overall survival in the abiraterone arm was significantly longer than in the docetaxel arm (14.8 *vs* 10.9 mo). However, abiraterone induces hyperaldosteronism by reduction of glucocorticoid following secondary ACTH overexpression. Although steroids are useful to protect such side effects, the combination of steroids with abiraterone could limit its use for patients with early-stage disease and longer life expectancies.

***TAK-700***

TAK-700 is a next-generation CYP17 inhibitor that requires no steroid administration. Because TAK-700 selectively targets 17, 20-lyase, inhibition of 17hydroxylase and reduction of glucocorticoids were smaller than those seen in patients treated with abiraterone[47,50]. A phase III clinical trial of TAK-700 for metastatic CRPC (ELM-PC5: Evaluation of the Lyase inhibitor orteronel in Metastatic Prostate Cancer 5) is ongoing. The results of interim analysis show that although overall survival was not significantly improved as a primary endpoint, progression-free survival was improved in the TAK-700 arm compared with the placebo arm (HR 0.755).

***TOK-001***

The chemical composition of TOK-001 is similar to that of abiraterone. In addition to 17-hydroxylase inhibitory activity, TOK-001 also has AR antagonistic action[51-53]. Phase I/II clinical trials for CRPC are ongoing.

***MDV3100***

MDV3100 binds to the AR directly and targets multiple steps in the AR signaling pathway, including translocation to the nucleus and binding of the AR to the ARE and coregulators. Because MDV3100 differs from agonistic anti-androgen, this compound does not induce anti-androgen withdrawal syndrome. MDV3100 induces the same action as the structural variant AR, which causes castration resistance; therefore, it is considered to be a 2nd generation anti-androgenic agent[54]. In a phase III double-blind, placebo-controlled trial (AFFIRM Clinical Trials), MDV3100 was superior in the proportion of patients with a reduction in PSA level by 50% or more, the quality-of-life response rate, progression free survival, and overall survival of men with metastatic CRPC after chemotherapy[55]. Based on these results, MDV3100 obtained approval for treatment of metastatic prostate cancer in Europe. In addition, recent clinical trial (PREVAIL Clinical Trials) showed that MDV3100 significantly decreased the risk of radiographic progression and prolonged overall survival in men with metastatic CRPC who have not received chemotherapy[56].

**DEVELOPMENT OF THERAPEUTIC DRUGS THAT TARGET THE ANDROGEN RESPONSIVE GENES**

The goal of the AR signaling pathway is the transcriptional activation of target genes (androgen-responsive genes). The overexpression of the androgen-responsive genes is the main cause of cancer progression regardless of the presence or absence of castration resistance. We have reported the results of the functional analysis of novel androgen responsive genes and AR coregulators that influence the progression of prostate cancer[57-62]. Here, we introduce a part of these studies, including therapeutic medicines.

***ARFGAP3***

ARFGAP3 (ADP ribosylation factor GTPase-activating protein) is a novel androgen-regulated gene that is considered to be associated with regulation of the vesicular transport of the Golgi apparatus. In androgen-sensitive prostate cancer LNCaP cells, we observed induction of ARFGAP3 expression at the mRNA and protein levels in response to stimulation with 100 nM DHT[59]. In functional analyses using LNCaP cells, the increased expression of ARFGAP3 was associated with cell growth, the G1/S cell cycle progression and cell migration. In addition, we found that ARFGAP3 interacted with paxillin as an AR coactivator, and enhanced migration activity and AR activity in LNCaP cells[59]. These findings suggest that ARFGAP3 is a novel androgen-regulated gene that can promote prostate cancer cell proliferation and migration in collaboration with paxillin.

***Octamer transcription factor 1***

Octamer transcription factor 1 (Oct1) is a ubiquitous member of the POU-homeodomain family. Although Oct1 does not demonstrate androgenic responsiveness, it works as a coregulator of the AR, binding to neighbors of the ARE and regulating AR activity[29]. We found that Oct1 is expressed in the nuclei of LNCaP cells using immunocytochemistry. SiRNA silencing of Oct1 inhibited the proliferation in LNCaP cells[60]. In addition, using surgical specimens, we found a positive correlation between Oct1 immunoreactivity in samples with a high Gleason score and AR immunoreactivity. Moreover, patients with high immunoreactivities of both Oct1 and AR exhibited poorer cancer-specific survival[60]. These results demonstrate that Oct1 might be a prognostic factor for prostate cancer and a contributing factor for increased AR sensitivity and castration resistance.

***Pyrrole-imidazole polyamides***

Pyrrole-imidazole (PI) polyamides are small synthetic molecules that recognize and attach to the minor groove of DNA to inhibit DNA-transcription factor interactions with high affinity and sequence specificity[63-65]. DNA recognition by PI polyamides depends on a code of side-by-side pairing of pyrrole and imidazole in the hairpin structure. Various types of sequence-specific PI polyamides have recently been developed to control gene expression[66-69]. One of the most important advantages of PI polyamide is their resistance to biological degradation by nucleases and proteases compared to nucleic acid medicines, including siRNA. In addition, PI polyamides could be efficiently delivered to cell nuclei without any specific drug delivery system. Another important advantage is the safety of PI polyamides when they are injected intravenously or via peritoneal to mice or rats[66,67]. PI polyamide that recognizes androgen response elements (AREs) suppresses DHT-dependent gene expression in LNCaP cells[70]. In addition, this polyamide was reported to inhibit the binding of RNA polymerase II to the transcription start site of AR-driving genes[71]. These reports indicate that PI polyamides could be a powerful tool in the development of molecularly targeted therapeutics for androgen responsive genes/AR coregulators in prostate cancer.

**CONCLUSION**

The clinical challenges in prostate cancer are currently focused on controlling the action of the AR, which plays an important role in the development of hormone therapy naïve prostate cancer and also CRPC. Recent evidence shows that CRPC cells are still dependent on AR activity after ADT. Selective inhibition of the AR signaling pathway by typical ADT induced a bypass mechanism to activate the AR in low dose or in the absence of DHT, and thereby restore AR-dependent cellular proliferation. Thus, blocking the AR with second-generation AR antagonists has the potential to treat CRPC because of stronger and more durable inhibition of transcriptional activity than previous compounds. Various functional studies, including our reports, have cited androgen-regulated genes and AR collaborating factors, such as Oct1, as preferable candidates for biomarkers and therapeutic targets for CRPC. We believe future investigations of the AR signaling pathway and novel therapeutics targeting this pathway are mainstays for considering new strategies to treat CRPC.

**REFERENCES**

1 **Siegel R**, Naishadham D, Jemal A. Cancer statistics, 2013. *CA Cancer J Clin* 2013; **63**: 11-30 [PMID: 23335087 DOI: 10.3322/caac.21166]

2 **Hobisch A**, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A. Androgen receptor status of lymph node metastases from prostate cancer. *Prostate* 1996; **28**: 129-135 [PMID: 8604394 DOI: 10.1002/(SICI)1097-0045(199602)28: 2<129: : AID-PROS9>3.0.CO; 2-B]

3 **Tilley WD**, Lim-Tio SS, Horsfall DJ, Aspinall JO, Marshall VR, Skinner JM. Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: measurement by color video image analysis. *Cancer Res* 1994; **54**: 4096-4102 [PMID: 7518349]

4 **van der Kwast TH**, Têtu B. Androgen receptors in untreated and treated prostatic intraepithelial neoplasia. *Eur Urol* 1996; **30**: 265-268 [PMID: 8875210]

5 **Huggins C**. EFFECT OF ORCHIECTOMY AND IRRADIATION ON CANCER OF THE PROSTATE. *Ann Surg* 1942; **115**: 1192-1200 [PMID: 17858048]

6 **Huggins C,** Hodges CV. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. *Cancer Res* 1941; **1**: 293-297

7 **Trapman J**, Brinkmann AO. The androgen receptor in prostate cancer. *Pathol Res Pract* 1996; **192**: 752-760 [PMID: 8880876]

8 **Taplin ME**, Balk SP. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. *J Cell Biochem* 2004; **91**: 483-490 [PMID: 14755679 DOI: 10.1002/jcb.10653]

9 **Feldman BJ**, Feldman D. The development of androgen-independent prostate cancer. *Nat Rev Cancer* 2001; **1**: 34-45 [PMID: 11900250 DOI: 10.1038/35094009]

10 **Denmeade SR**, Isaacs JT. A history of prostate cancer treatment. *Nat Rev Cancer* 2002; **2**: 389-396 [PMID: 12044015 DOI: 10.1038/nrc801]

11 **Arnold JT**, Isaacs JT. Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. *Endocr Relat Cancer* 2002; **9**: 61-73 [PMID: 11914183]

12 **Hotte SJ**, Saad F. Current management of castrate-resistant prostate cancer. *Curr Oncol* 2010; **17 Suppl 2**: S72-S79 [PMID: 20882137]

13 **Kirby M**, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. *Int J Clin Pract* 2011; **65**: 1180-1192 [PMID: 21995694 DOI: 10.1111/j.1742-1241.2011.02799.x]

14 **Tsai MJ**, O'Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. *Annu Rev Biochem* 1994; **63**: 451-486 [PMID: 7979245 DOI: 10.1146/annurev.bi.63.070194.002315]

15 **Jenster G**, van der Korput HA, Trapman J, Brinkmann AO. Identification of two transcription activation units in the N-terminal domain of the human androgen receptor. *J Biol Chem* 1995; **270**: 7341-7346 [PMID: 7706276]

16 **Ma H**, Hong H, Huang SM, Irvine RA, Webb P, Kushner PJ, Coetzee GA, Stallcup MR. Multiple signal input and output domains of the 160-kilodalton nuclear receptor coactivator proteins. *Mol Cell Biol* 1999; **19**: 6164-6173 [PMID: 10454563]

17 **Bevan CL**, Hoare S, Claessens F, Heery DM, Parker MG. The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1. *Mol Cell Biol* 1999; **19**: 8383-8392 [PMID: 10567563]

18 **Alen P**, Claessens F, Verhoeven G, Rombauts W, Peeters B. The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription. *Mol Cell Biol* 1999; **19**: 6085-6097 [PMID: 10454556]

19 **Chamberlain NL**, Whitacre DC, Miesfeld RL. Delineation of two distinct type 1 activation functions in the androgen receptor amino-terminal domain. *J Biol Chem* 1996; **271**: 26772-26778 [PMID: 8900157]

20 **Langley E**, Zhou ZX, Wilson EM. Evidence for an anti-parallel orientation of the ligand-activated human androgen receptor dimer. *J Biol Chem* 1995; **270**: 29983-29990 [PMID: 8530400]

21 **Doesburg P**, Kuil CW, Berrevoets CA, Steketee K, Faber PW, Mulder E, Brinkmann AO, Trapman J. Functional in vivo interaction between the amino-terminal, transactivation domain and the ligand binding domain of the androgen receptor. *Biochemistry* 1997; **36**: 1052-1064 [PMID: 9033395 DOI: 10.1021/bi961775g]

22 **Ikonen T**, Palvimo JJ, Jänne OA. Interaction between the amino- and carboxyl-terminal regions of the rat androgen receptor modulates transcriptional activity and is influenced by nuclear receptor coactivators. *J Biol Chem* 1997; **272**: 29821-29828 [PMID: 9368054]

23 **Berrevoets CA**, Doesburg P, Steketee K, Trapman J, Brinkmann AO. Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor2). *Mol Endocrinol* 1998; **12**: 1172-1183 [PMID: 9717843]

24 **He B**, Kemppainen JA, Voegel JJ, Gronemeyer H, Wilson EM. Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH(2)-terminal domain. *J Biol Chem* 1999; **274**: 37219-37225 [PMID: 10601285]

25 **McEwan IJ**, Gustafsson J. Interaction of the human androgen receptor transactivation function with the general transcription factor TFIIF. *Proc Natl Acad Sci U S A* 1997; **94**: 8485-8490 [PMID: 9238003]

26 **Lee DK**, Duan HO, Chang C. From androgen receptor to the general transcription factor TFIIH. Identification of cdk activating kinase (CAK) as an androgen receptor NH(2)-terminal associated coactivator. *J Biol Chem* 2000; **275**: 9308-9313 [PMID: 10734072]

27 **Aarnisalo P**, Palvimo JJ, Jänne OA. CREB-binding protein in androgen receptor-mediated signaling. *Proc Natl Acad Sci U S A* 1998; **95**: 2122-2127 [PMID: 9482849]

28 **Frønsdal K**, Engedal N, Slagsvold T, Saatcioglu F. CREB binding protein is a coactivator for the androgen receptor and mediates cross-talk with AP-1. *J Biol Chem* 1998; **273**: 31853-31859 [PMID: 9822653]

29 **Wang Q**, Li W, Liu XS, Carroll JS, Jänne OA, Keeton EK, Chinnaiyan AM, Pienta KJ, Brown M. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. *Mol Cell* 2007; **27**: 380-392 [PMID: 17679089 DOI: S1097-2765(07)00373-5]

30 **Mangelsdorf DJ**, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM. The nuclear receptor superfamily: the second decade. *Cell* 1995; **83**: 835-839 [PMID: 8521507 DOI: 0092-8674(95)90199-X]

31 **Claessens F**, Denayer S, Van Tilborgh N, Kerkhofs S, Helsen C, Haelens A. Diverse roles of androgen receptor (AR) domains in AR-mediated signaling. *Nucl Recept Signal* 2008; **6**: e008 [PMID: 18612376 DOI: 10.1621/nrs.06008]

32 **Shaffer PL**, Jivan A, Dollins DE, Claessens F, Gewirth DT. Structural basis of androgen receptor binding to selective androgen response elements. *Proc Natl Acad Sci U S A* 2004; **101**: 4758-4763 [PMID: 15037741 DOI: 10.1073/pnas.0401123101]

33 **Umesono K**, Evans RM. Determinants of target gene specificity for steroid/thyroid hormone receptors. *Cell* 1989; **57**: 1139-1146 [PMID: 2500251]

34 **Heery DM**, Kalkhoven E, Hoare S, Parker MG. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. *Nature* 1997; **387**: 733-736 [PMID: 9192902 DOI: 10.1038/42750]

35 **Duff J**, Davies P, Watt K, McEwan IJ. Structural dynamics of the human androgen receptor: implications for prostate cancer and neurodegenerative disease. *Biochem Soc Trans* 2006; **34**: 1098-1102 [PMID: 17073759 DOI: 10.1042/BST0341098]

36 **Dehm SM**, Tindall DJ. Molecular regulation of androgen action in prostate cancer. *J Cell Biochem* 2006; **99**: 333-344 [PMID: 16518832 DOI: 10.1002/jcb.20794]

37 **Taplin ME**, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. *N Engl J Med* 1995; **332**: 1393-1398 [PMID: 7723794 DOI: 10.1056/NEJM199505253322101]

38 **Taplin ME**, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW, Vogelzang NJ, Small EJ. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. *J Clin Oncol* 2003; **21**: 2673-2678 [PMID: 12860943 DOI: 10.1200/JCO.2003.11.102]

39 **Buchanan G**, Greenberg NM, Scher HI, Harris JM, Marshall VR, Tilley WD. Collocation of androgen receptor gene mutations in prostate cancer. *Clin Cancer Res* 2001; **7**: 1273-1281 [PMID: 11350894]

40 **Smith DF**, Toft DO. Minireview: the intersection of steroid receptors with molecular chaperones: observations and questions. *Mol Endocrinol* 2008; **22**: 2229-2240 [PMID: 18451092 DOI: 10.1210/me.2008-0089]

41 **Oñate SA**, Tsai SY, Tsai MJ, O'Malley BW. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. *Science* 1995; **270**: 1354-1357 [PMID: 7481822]

42 **Heemers HV**, Tindall DJ. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. *Endocr Rev* 2007; **28**: 778-808 [PMID: 17940184 DOI: 10.1210/er.2007-0019]

43 **Agoulnik IU**, Weigel NL. Coactivator selective regulation of androgen receptor activity. *Steroids* 2009; **74**: 669-674 [PMID: 19463689 DOI: 10.1016/j.steroids.2009.02.007]

44 **Stanbrough M**, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. *Cancer Res* 2006; **66**: 2815-2825 [PMID: 16510604 DOI: 10.1158/0008-5472.CAN-05-4000]

45 **Buchanan G**, Irvine RA, Coetzee GA, Tilley WD. Contribution of the androgen receptor to prostate cancer predisposition and progression. *Cancer Metastasis Rev* 2001; **20**: 207-223 [PMID: 12085963]

46 **Cai C**, He HH, Chen S, Coleman I, Wang H, Fang Z, Chen S, Nelson PS, Liu XS, Brown M, Balk SP. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. *Cancer Cell* 2011; **20**: 457-471 [PMID: 22014572 DOI: 10.1016/j.ccr.2011.09.001]

47 **Yamaoka M**, Hara T, Kusaka M. Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer. *Clin Cancer Res* 2010; **16**: 4319-4324 [PMID: 20647476 DOI: 10.1158/1078-0432.CCR-10-0255]

48 **Small EJ**, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, Gable P, Torti FM, Kaplan E, Vogelzang NJ. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). *J Clin Oncol* 2004; **22**: 1025-1033 [PMID: 15020604 DOI: 10.1200/JCO.2004.06.037]

49 **de Bono JS**, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI. Abiraterone and increased survival in metastatic prostate cancer. *N Engl J Med* 2011; **364**: 1995-2005 [PMID: 21612468 DOI: 10.1056/NEJMoa1014618]

50 **Kaku T**, Hitaka T, Ojida A, Matsunaga N, Adachi M, Tanaka T, Hara T, Yamaoka M, Kusaka M, Okuda T, Asahi S, Furuya S, Tasaka A. Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer. *Bioorg Med Chem* 2011; **19**: 6383-6399 [PMID: 21978946 DOI: 10.1016/j.bmc.2011.08.066]

51 **Vasaitis T**, Belosay A, Schayowitz A, Khandelwal A, Chopra P, Gediya LK, Guo Z, Fang HB, Njar VC, Brodie AM. Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. *Mol Cancer Ther* 2008; **7**: 2348-2357 [PMID: 18723482 DOI: 10.1158/1535-7163.MCT-08-0230]

52 **Vasaitis TS**, Bruno RD, Njar VC. CYP17 inhibitors for prostate cancer therapy. *J Steroid Biochem Mol Biol* 2011; **125**: 23-31 [PMID: 21092758 DOI: 10.1016/j.jsbmb.2010.11.005]

53 **Handratta VD**, Vasaitis TS, Njar VC, Gediya LK, Kataria R, Chopra P, Newman D, Farquhar R, Guo Z, Qiu Y, Brodie AM. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. *J Med Chem* 2005; **48**: 2972-2984 [PMID: 15828836 DOI: 10.1021/jm040202w]

54 **Watson PA**, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K, Sawyers CL. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. *Proc Natl Acad Sci U S A* 2010; **107**: 16759-16765 [PMID: 20823238 DOI: 10.1073/pnas.1012443107]

55 **Scher HI**, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS. Increased survival with enzalutamide in prostate cancer after chemotherapy. *N Engl J Med* 2012; **367**: 1187-1197 [PMID: 22894553 DOI: 10.1056/NEJMoa1207506]

56 [**Beer TM**](http://www.ncbi.nlm.nih.gov/pubmed?term=Beer%20TM%5BAuthor%5D&cauthor=true&cauthor_uid=24881730)**,**[Armstrong AJ](http://www.ncbi.nlm.nih.gov/pubmed?term=Armstrong%20AJ%5BAuthor%5D&cauthor=true&cauthor_uid=24881730), [Rathkopf DE](http://www.ncbi.nlm.nih.gov/pubmed?term=Rathkopf%20DE%5BAuthor%5D&cauthor=true&cauthor_uid=24881730), [Loriot Y](http://www.ncbi.nlm.nih.gov/pubmed?term=Loriot%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=24881730), [Sternberg CN](http://www.ncbi.nlm.nih.gov/pubmed?term=Sternberg%20CN%5BAuthor%5D&cauthor=true&cauthor_uid=24881730), [Higano CS](http://www.ncbi.nlm.nih.gov/pubmed?term=Higano%20CS%5BAuthor%5D&cauthor=true&cauthor_uid=24881730), [Iversen P](http://www.ncbi.nlm.nih.gov/pubmed?term=Iversen%20P%5BAuthor%5D&cauthor=true&cauthor_uid=24881730), [Bhattacharya S](http://www.ncbi.nlm.nih.gov/pubmed?term=Bhattacharya%20S%5BAuthor%5D&cauthor=true&cauthor_uid=24881730), [Carles J](http://www.ncbi.nlm.nih.gov/pubmed?term=Carles%20J%5BAuthor%5D&cauthor=true&cauthor_uid=24881730), [Chowdhury S](http://www.ncbi.nlm.nih.gov/pubmed?term=Chowdhury%20S%5BAuthor%5D&cauthor=true&cauthor_uid=24881730), [Davis ID](http://www.ncbi.nlm.nih.gov/pubmed?term=Davis%20ID%5BAuthor%5D&cauthor=true&cauthor_uid=24881730), [de Bono JS](http://www.ncbi.nlm.nih.gov/pubmed?term=de%20Bono%20JS%5BAuthor%5D&cauthor=true&cauthor_uid=24881730), [Evans CP](http://www.ncbi.nlm.nih.gov/pubmed?term=Evans%20CP%5BAuthor%5D&cauthor=true&cauthor_uid=24881730),[Fizazi K](http://www.ncbi.nlm.nih.gov/pubmed?term=Fizazi%20K%5BAuthor%5D&cauthor=true&cauthor_uid=24881730), [Joshua AM](http://www.ncbi.nlm.nih.gov/pubmed?term=Joshua%20AM%5BAuthor%5D&cauthor=true&cauthor_uid=24881730), [Kim CS](http://www.ncbi.nlm.nih.gov/pubmed?term=Kim%20CS%5BAuthor%5D&cauthor=true&cauthor_uid=24881730), [Kimura G](http://www.ncbi.nlm.nih.gov/pubmed?term=Kimura%20G%5BAuthor%5D&cauthor=true&cauthor_uid=24881730), [Mainwaring P](http://www.ncbi.nlm.nih.gov/pubmed?term=Mainwaring%20P%5BAuthor%5D&cauthor=true&cauthor_uid=24881730), [Mansbach H](http://www.ncbi.nlm.nih.gov/pubmed?term=Mansbach%20H%5BAuthor%5D&cauthor=true&cauthor_uid=24881730), [Miller K](http://www.ncbi.nlm.nih.gov/pubmed?term=Miller%20K%5BAuthor%5D&cauthor=true&cauthor_uid=24881730), [Noonberg SB](http://www.ncbi.nlm.nih.gov/pubmed?term=Noonberg%20SB%5BAuthor%5D&cauthor=true&cauthor_uid=24881730), [Perabo F](http://www.ncbi.nlm.nih.gov/pubmed?term=Perabo%20F%5BAuthor%5D&cauthor=true&cauthor_uid=24881730), [Phung D](http://www.ncbi.nlm.nih.gov/pubmed?term=Phung%20D%5BAuthor%5D&cauthor=true&cauthor_uid=24881730), [Saad F](http://www.ncbi.nlm.nih.gov/pubmed?term=Saad%20F%5BAuthor%5D&cauthor=true&cauthor_uid=24881730), [Scher HI](http://www.ncbi.nlm.nih.gov/pubmed?term=Scher%20HI%5BAuthor%5D&cauthor=true&cauthor_uid=24881730), [Taplin ME](http://www.ncbi.nlm.nih.gov/pubmed?term=Taplin%20ME%5BAuthor%5D&cauthor=true&cauthor_uid=24881730), [Venner PM](http://www.ncbi.nlm.nih.gov/pubmed?term=Venner%20PM%5BAuthor%5D&cauthor=true&cauthor_uid=24881730),[Tombal B](http://www.ncbi.nlm.nih.gov/pubmed?term=Tombal%20B%5BAuthor%5D&cauthor=true&cauthor_uid=24881730). Enzalutamide in Metastatic Prostate Cancer before Chemotherapy. *N Engl J Med* 2014 [PMID: 24881730 DOI: 10.1056/NEJMoa1405095]

57 **Murata T**, Takayama K, Katayama S, Urano T, Horie-Inoue K, Ikeda K, Takahashi S, Kawazu C, Hasegawa A, Ouchi Y, Homma Y, Hayashizaki Y, Inoue S. miR-148a is an androgen-responsive microRNA that promotes LNCaP prostate cell growth by repressing its target CAND1 expression. *Prostate Cancer Prostatic Dis* 2010; **13**: 356-361 [PMID: 20820187 DOI: 10.1038/pcan.2010.32]

58 **Murata T**, Takayama K, Urano T, Fujimura T, Ashikari D, Obinata D, Horie-Inoue K, Takahashi S, Ouchi Y, Homma Y, Inoue S. 14-3-3ζ, a novel androgen-responsive gene, is upregulated in prostate cancer and promotes prostate cancer cell proliferation and survival. *Clin Cancer Res* 2012; **18**: 5617-5627 [PMID: 22904106 DOI: 10.1158/1078-0432.CCR-12-0281]

59 **Obinata D**, Takayama K, Urano T, Murata T, Ikeda K, Horie-Inoue K, Ouchi Y, Takahashi S, Inoue S. ARFGAP3, an androgen target gene, promotes prostate cancer cell proliferation and migration. *Int J Cancer* 2012; **130**: 2240-2248 [PMID: 21647875 DOI: 10.1002/ijc.26224]

60 **Obinata D**, Takayama K, Urano T, Murata T, Kumagai J, Fujimura T, Ikeda K, Horie-Inoue K, Homma Y, Ouchi Y, Takahashi S, Inoue S. Oct1 regulates cell growth of LNCaP cells and is a prognostic factor for prostate cancer. *Int J Cancer* 2012; **130**: 1021-1028 [PMID: 21387309 DOI: 10.1002/ijc.26043]

61 **Takayama K**, Horie-Inoue K, Suzuki T, Urano T, Ikeda K, Fujimura T, Takahashi S, Homma Y, Ouchi Y, Inoue S. TACC2 is an androgen-responsive cell cycle regulator promoting androgen-mediated and castration-resistant growth of prostate cancer. *Mol Endocrinol* 2012; **26**: 748-761 [PMID: 22456197 DOI: 10.1210/me.2011-1242]

62 **Takayama K**, Tsutsumi S, Suzuki T, Horie-Inoue K, Ikeda K, Kaneshiro K, Fujimura T, Kumagai J, Urano T, Sakaki Y, Shirahige K, Sasano H, Takahashi S, Kitamura T, Ouchi Y, Aburatani H, Inoue S. Amyloid precursor protein is a primary androgen target gene that promotes prostate cancer growth. *Cancer Res* 2009; **69**: 137-142 [PMID: 19117996 DOI: 10.1158/0008-5472.CAN-08-3633]

63 **Dervan PB**, Edelson BS. Recognition of the DNA minor groove by pyrrole-imidazole polyamides. *Curr Opin Struct Biol* 2003; **13**: 284-299 [PMID: 12831879]

64 **Dervan PB**. Molecular recognition of DNA by small molecules. *Bioorg Med Chem* 2001; **9**: 2215-2235 [PMID: 11553460]

65 **Trauger JW**, Baird EE, Dervan PB. Recognition of DNA by designed ligands at subnanomolar concentrations. *Nature* 1996; **382**: 559-561 [PMID: 8700233 DOI: 10.1038/382559a0]

66 **Wang X**, Nagase H, Watanabe T, Nobusue H, Suzuki T, Asami Y, Shinojima Y, Kawashima H, Takagi K, Mishra R, Igarashi J, Kimura M, Takayama T, Fukuda N, Sugiyama H. Inhibition of MMP-9 transcription and suppression of tumor metastasis by pyrrole-imidazole polyamide. *Cancer Sci* 2010; **101**: 759-766 [PMID: 20085585 DOI: 10.1111/j.1349-7006.2009.01435.x]

67 **Matsuda H**, Fukuda N, Ueno T, Katakawa M, Wang X, Watanabe T, Matsui S, Aoyama T, Saito K, Bando T, Matsumoto Y, Nagase H, Matsumoto K, Sugiyama H. Transcriptional inhibition of progressive renal disease by gene silencing pyrrole-imidazole polyamide targeting of the transforming growth factor-β1 promoter. *Kidney Int* 2011; **79**: 46-56 [PMID: 20861821 DOI: 10.1038/ki.2010.330]

68 **Murty MS**, Sugiyama H. Biology of N-methylpyrrole-N-methylimidazole hairpin polyamide. *Biol Pharm Bull* 2004; **27**: 468-474 [PMID: 15056849]

69 **Sato A**, Nagase H, Obinata D, Fujiwara K, Fukuda N, Soma M, Yamaguchi K, Kawata N, Takahashi S. Inhibition of MMP-9 using a pyrrole-imidazole polyamide reduces cell invasion in renal cell carcinoma. *Int J Oncol* 2013; **43**: 1441-1446 [PMID: 23969530 DOI: 10.3892/ijo.2013.2073]

70 **Nickols NG**, Dervan PB. Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide. *Proc Natl Acad Sci U S A* 2007; **104**: 10418-10423 [PMID: 17566103 DOI: 10.1073/pnas.0704217104]

71 **Yang F**, Nickols NG, Li BC, Marinov GK, Said JW, Dervan PB. Antitumor activity of a pyrrole-imidazole polyamide. *Proc Natl Acad Sci U S A* 2013; **110**: 1863-1868 [PMID: 23319609 DOI: 10.1073/pnas.1222035110]

**P-Reviewer:** Liu G, Pastore AL, Wu KM **S-Editor:** Ji FF **L-Editor: E-Editor:**

Macintosh HD:Users:Obinata:Dropbox:Documents:論文:AR review:Fig:図3a.ai

**Figure 1 Schematic view of the therapeutic medicines targeting for androgen receptor signaling pathways.** ACTH: Adrenocorticotropic hormone; AR: Androgen receptor; ARE: Androgen response element; LH: Luteinizing hormone; LHRH: Luteinizing hormone-releasing hormone.